ReoPro GPIIb/IIIa inhibitor of platelets data

As reported at the meeting of the European Society of Cardiology in Stockholm, patients treated with the agent and who had angioplasty had a 74 percent reduced risk of a composite end point

Read the full 331 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE